Pure Global

Efficacy and Safety of Telitacicept for Prevention of Flares in SLE Patients - Trial NCT06394063

Access comprehensive clinical trial information for NCT06394063 through Pure Global AI's free database. This phase not specified trial is sponsored by RenJi Hospital and is currently Not yet recruiting. The study focuses on Systemic Lupus Erythematosus. Target enrollment is 176 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.

Free Database
Powered by Pure Global AI
840K+ Trials
NCT06394063
Not yet recruiting
biological
Trial Details
ClinicalTrials.gov • NCT06394063
View on ClinicalTrials.gov
Pure Global
DJ Fang

DJ Fang

MedTech Regulatory Expert

Need help with 30+ markets registration?

Pricing
Efficacy and Safety of Telitacicept for Prevention of Flares in SLE Patients
A Randomized, Double-blind, Placebo-controlled Trial of Efficacy and Safety of Low-dose Telitacicept for Prevention of Flares in SLE Patients With Low Disease Activity

Study Focus

Telitacicept

Interventional

biological

Sponsor & Location

RenJi Hospital

Timeline & Enrollment

N/A

Jun 30, 2024

Jun 30, 2027

176 participants

Primary Outcome

Percentage of patients with disease flares

Summary

This study is a randomized, double-blind, placebo-controlled single-center clinical trial.
 The aim of this study is to investigate the efficacy and safety of low-dose telitacicept for
 prevention of flares in SLE patients with low disease activity.

ICD-10 Classifications

Systemic lupus erythematosus
Systemic lupus erythematosus, unspecified
Lupus erythematosus
Systemic lupus erythematosus with organ or system involvement
Other forms of systemic lupus erythematosus

Data Source

ClinicalTrials.gov

NCT06394063

Non-Device Trial